These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16270039)

  • 1. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
    McClure R; Mai M; Lasho T
    Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis.
    Murugesan G; Aboudola S; Szpurka H; Verbic MA; Maciejewski JP; Tubbs RR; Hsi ED
    Am J Clin Pathol; 2006 Apr; 125(4):625-33. PubMed ID: 16627272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
    McLornan D; Percy M; McMullin MF
    Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.
    Lay M; Mariappan R; Gotlib J; Dietz L; Sebastian S; Schrijver I; Zehnder JL
    J Mol Diagn; 2006 Jul; 8(3):330-4. PubMed ID: 16825505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
    Berger R
    Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
    [No Abstract]   [Full Text] [Related]  

  • 8. A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders.
    Di Ianni M; Moretti L; Del Papa B; Gaozza E; Bell AS; Falzetti F; Tabilio A
    Leukemia; 2006 Oct; 20(10):1895-7. PubMed ID: 16900208
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.
    James C; Delhommeau F; Marzac C; Teyssandier I; Couédic JP; Giraudier S; Roy L; Saulnier P; Lacroix L; Maury S; Tulliez M; Vainchenker W; Ugo V; Casadevall N
    Leukemia; 2006 Feb; 20(2):350-3. PubMed ID: 16341032
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
    Greiner TC
    Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
    [No Abstract]   [Full Text] [Related]  

  • 11. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ; McMullin MF
    Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
    Vizmanos JL; Ormazábal C; Larráyoz MJ; Cross NC; Calasanz MJ
    Leukemia; 2006 Mar; 20(3):534-5. PubMed ID: 16408096
    [No Abstract]   [Full Text] [Related]  

  • 13. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.
    Bellosillo B; Besses C; Florensa L; Solé F; Serrano S
    Leukemia; 2006 Apr; 20(4):736-7. PubMed ID: 16453004
    [No Abstract]   [Full Text] [Related]  

  • 14. Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.
    Vannucchi AM; Guglielmelli P; Antonioli E; Mappa S; Pancrazzi A; Bogani C; Ponziani V; Bosi A
    Br J Haematol; 2006 Mar; 132(5):652-4; author reply 654. PubMed ID: 16445842
    [No Abstract]   [Full Text] [Related]  

  • 15. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
    Lasho TL; Mesa R; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
    [No Abstract]   [Full Text] [Related]  

  • 16. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system.
    Olsen RJ; Tang Z; Farkas DH; Bernard DW; Zu Y; Chang CC
    Arch Pathol Lab Med; 2006 Jul; 130(7):997-1003. PubMed ID: 16831057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
    Rossi D; Deambrogi C; Capello D; Cerri M; Lunghi M; Parvis G; Saglio G; Gaidano G; Cilloni D
    Br J Haematol; 2006 Oct; 135(2):267-8. PubMed ID: 16956348
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.
    Stevenson WS; Hoyt R; Bell A; Guipponi M; Juneja S; Grigg AP; Curtis DJ; Scott HS; Szer J; Alexander WS; Tuckfield A; Roberts AW
    Pathology; 2006 Aug; 38(4):336-42. PubMed ID: 16916724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.